🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great discussion and wonderful to see a former fellow with us, Akeem Lewis, discuss. I came here on a J-1 visa and got my H1B and ultimately Green Card working at the VA which was an excellent place to start the career and for me, was a fun place to work with the best patients.

Mayo Clinic Comprehensive Cancer Center will lead in more than 60 sessions at #ASCO25, including 59 Mayo Clinic-authored abstracts highlighting advancements in #CancerCare. These are some of the highlights you won't want to miss: newsnetwork.mayoclinic.org/discussion/may…

Thrilled to be the discussant for the #NeuroendocrineCancer orals at #ASCO25 from Thor Halfdanarson and Jaume Capdevila 🔥 Neuroendocrine Neoplasms are finally stepping into the spotlight of early-phase oncology—and it’s about time. The science is strong, the momentum is real. Don’t miss

#ASCO2025 for a half-day. Back home tonight for a high schooler’s graduation tomorrow. Some things are more important than oncology… 😀 Want to learn about alpha particles in NETs and DLL3 as a NEN target? Jaume Capdevila, Heloisa Soares MD and I will discuss this afternoon…

"Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology," featuring an abstract presentation by Thor Halfdanarson. Details: meetings.asco.org/2025-asco-annu…

Great to see NEN trials presented #ASCO25 in Developmental Therapeutics Jaume Capdevila Obrixtamig in DLL3high pretreated epNEC; 40% ORR & 7.9 mo DoR; unmet disease group Neuroendocrine Cancer UK #NotJustNECancer

Do. Not. Miss. That!

PRRT is a very effective for well-differentiated NETs but associated with a low risk of treatment related myeloid neoplasms ( t-MN ). If you are interested in learning more, this is the review for you... 😀 Bassam Sonbol Mrinal Patnaik yael kusne MD PhD erc.bioscientifica.com/view/journals/…

What works for malignant insulinoma...? Actually, many things do. If you want to learn more, Dr. Regina Koch has the paper for you. In this 57 pt retrospective study, PRRT, CAPTEM and everolimus all had activity for hypoglycemia and OS can be quite long. erc.bioscientifica.com/view/journals/…

The next frontier in radioligand therapy (RLT), radioligand-antibody drug conjugates...? Interesting data targeting TROP2 and HER2 in xenograft mouse models with orthotopic breast tumors. I am certainly keeping an eye on how this develops... aacrjournals.org/mct/article/24…

Neoadj chemo (NAC) for resectable pancreatic adenocarcinoma. Small study, non-comparative RCT-II and as such does not answer the question of all should have NAC but at least it is feasible.Kudos to Journal of Clinical Oncology for automatically including appendix material! ascopubs.org/doi/pdf/10.120…

Want a quick update in medical oncology on July 19 (with some heme updates in the mix)...? If so, we have the course for you! I can promise excellent content/speakers and there is a livestream (virtual) option too for those who cannot attend in person. ce.mayo.edu/hematology-and…

Interested in listening to new music on your way riding home from work…? Something that’s good with the gorgeous sunset? Try Anatolian Rock😀 There is even an Apple Music playlist for that. Thanks FIP 📻 (the best radio station in the universe) for the intro to this genre.

Join us for this Saturday's VIRTUAL conference, a unique opportunity to hear from 22 NET experts from across No America! Julie Hallet Callisia Clarke MD Alexandra Gangi, MD Pamela Kunz, MD, FASCO Thor Halfdanarson Aman Chauhan Osman Ahmed Daneng Li Dr. Andrew Hendifar Nadine Mallak, MD Erik Mittra, MD, PhD

Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis thelancet.com/journals/landi… #MEN1 #OpenAccess

I still get excited about good clinical papers! 😀I have been waiting for this one with much anticipation... For anyone taking care of patients with MEN1 or interested in learning more, this is the document you need. Kudos to the team that got this done including Mark Lewis, MD, FASCO !

Excellent work and important addition to the literature of malignant insulinoma. The short summary is, PRRT works! Very similar results to what we recently reported... erc.bioscientifica.com/view/journals/…?

I just posted highly valuable guidelines on MEN1, checked my e-mail and found this... Update in surveillance for VHL. If you are interested in the NET as a manifestation of MEN1, there is a good chance you might be interested in VHL too... aacrjournals.org/clincancerres/…